The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Open accessAbstract
Importance: This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors. Objective: To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. Design, Setting, and Participants: This follow-up of a randomized phase 3 trial analyzed 3-year overall survival data from the randomized, controlled, double-blind CheckMate 066 phase 3 clinical trial. For this ongoing, multicenter academic institution trial, patients were enrolled from January 2013 through February 2014. Eligible patients were 18 years or older with confirmed unresectable previously untreated stage III or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 but without a BRAF mutation. Interventions: Patients were treated until progression or unacceptable toxic events with nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks) or dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks). Main Outcome and Measure: Overall survival. Results: At minimum follow-ups of 38.4 months among 210 participants in the nivolumab group (median age, 64 years [range, 18-86 years]; 57.6% male) and 38.5 months among 208 participants in the dacarbazine group (median age, 66 years [range, 25-87 years]; 60.1% male), 3-year overall survival rates were 51.2% (95% CI, 44.1%-57.9%) and 21.6% (95% CI, 16.1%-27.6%), respectively. The median overall survival was 37.5 months (95% CI, 25.5 months-not reached) in the nivolumab group and 11.2 months (95% CI, 9.6-13.0 months) in the dacarbazine group (hazard ratio, 0.46; 95% CI, 0.36-0.59; P < .001). Complete and partial responses, respectively, were reported for 19.0% (40 of 210) and 23.8% (50 of 210) of patients in the nivolumab group compared with 1.4% (3 of 208) and 13.0% (27 of 208) of patients in the dacarbazine group. Additional analyses were performed on outcomes with subsequent therapies. Treatment-related grade 3/4 adverse events occurred in 15.0% (31 of 206) of nivolumab-treated patients and in 17.6% (36 of 205) of dacarbazine-treated patients. There were no deaths due to study drug toxic effects. Conclusions and Relevance: Nivolumab led to improved 3-year overall survival vs dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. Trial Registration: ClinicalTrials.gov identifier: NCT01721772.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Self-citation
Cited by
Sorted by citations
Items 201–300 of 352
Nie, R., Yuan, S., Wang, Y., Zou, X., Chen, S., Li, S., Duan, J., Zhou, J., Chen, G., Luo, T., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920929583 · Cited by 8
Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature
Berciano‐Guerrero, M., Guardamagna, M., Pérez-Ruiz, E., Jurado, J. M., Barragán, I., & Rueda‐Domínguez, A. (2022) · Life · doi:10.3390/life12091302 · Cited by 9
The Era of Checkpoint Inhibition: Lessons Learned from Melanoma
Paschen, A., & Schadendorf, D. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_6 · Cited by 9
Self-citationCombinatorial Approaches to the Treatment of Advanced Melanoma
Munhoz, R. R., & Postow, M. A. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.015 · Cited by 8
Jennings, S., Anstey, S., Bower, J., Brewster, A. E., Buckman, J., Fenlon, D., Fitzsimmons, D. F., & Watts, T. E. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043750 · Cited by 8
Visconti, A., Rossi, N., Deriš, H., Lee, K. A., Hanić, M., Trbojević‐Akmačić, I., Thomas, A. M., Bolte, L. A., Björk, J. R., Hooiveld-Noeken, J. S., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10511-3 · Cited by 9
“The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced melanoma [17, 18], as well as other cancers [19], although a significant proportion of patients with melanoma are either non-responders or acquire resistance to ICI after an initial response [20].”
BackgroundLi, S., Yin, C., Yang, X., Lu, Y., Wang, C., & Liu, B. (2023) · Medicine · doi:10.1097/md.0000000000035380 · Cited by 8
Haywood, S., Garioch, J., Ramaiya, A., & Moncrieff, M. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08713-1 · Cited by 8
“The blockade of the PD-1 pathway is performed in melanoma treatment with the use of systemic anti-PD1 therapy.(21,22) The current study aimed to evaluate any link between the expression of BRAF mutation, CD8, PD-1, and PD-L1 in ITMs and clinical response to DPCP.”
MethodGray-Gaillard, E. F., Shah, A. A., Bingham, C. O., Elisseeff, J. H., Murray, J. C., Brahmer, J. R., Forde, P. M., Anagnostou, V., Mammen, J. S., & Cappelli, L. C. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03546-3 · Cited by 10
“Since the first approval of ICIs for melanoma in 2011, ICIs have shown unprecedented clinical responses and are being implemented as the standard of care for an increasing number of advanced malignancies [2–7].”
Watts, T. E., Roche, D., & Csontos, J. K. (2024) · Journal of Clinical Nursing · doi:10.1111/jocn.17154 · Cited by 8
“When evaluated against traditional anti-cancer treatments such as chemotherapy, consistent improvements in progression-free and overall survival have been reported, in people previously treated, and those new to any treatment (see, e.g. Antonia et al., 2018; Ascierto et al., 2019).”
Financial burden of high-cost immunotherapy among cancer survivors in Medicare
Owsley, K. M., & Bradley, C. J. (2025) · Journal of Cancer Survivorship · doi:10.1007/s11764-025-01797-2 · Cited by 7
Cybulska-Stopa, B., Ziętek, M., Kamińska‐Winciorek, G., Czarnecka, A. M., Piejko, K., Galus, Ł., Ziółkowska, B., Kieszko, S., Kempa-Kamińska, N., Calik, J., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000705 · Cited by 7
Self-citationGrumberg, V., Roze, S., Chevalier, J., Borrill, J., Gaudin, A.-F., & Branchoux, S. (2022) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462322000125 · Cited by 7
Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies
Fay, C. J., Jakuboski, S. H., McLellan, B. N., Allais, B. S., Semenov, Y. R., Larocca, C. A., & LeBoeuf, N. R. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00790-8 · Cited by 7
Самойленко, И. В., Демидов, Л. В., Moiseenko, F. V., Dvorkin, M. V., Demidova, S., Анатольевна, П. С., Stroyakovskiy, D., Kozlov, V. V., Odintsova, S. V., Kirtbaya, D., et al. (2023) · Journal of Modern Oncology · doi:10.26442/18151434.2023.3.202463 · Cited by 7
Spillane, A. J., Menzies, A. M., & van Akkooi, A. C. J. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08566-8 · Cited by 7
Huang, Y., Xie, W.-J., Fan, H., & Du, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.571135 · Cited by 7
Wu, J. H., Das, J., Kalra, M., & Ratto, B. E. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0249 · Cited by 7
Recent advancements in melanoma management
Krishnan, T., Menzies, A. M., & Roberts‐Thomson, R. (2021) · Internal Medicine Journal · doi:10.1111/imj.15228 · Cited by 7
Scolyer, R. A., Atkinson, V. G., Gyorki, D. E., Lambie, D., O'Toole, S. A., Saw, R. P. M., Amanuel, B., Angel, C. M., Button‐Sloan, A. E., Carlino, M. S., et al. (2021) · Pathology · doi:10.1016/j.pathol.2021.11.002 · Cited by 7
Self-citationBlank, C. U., Wong, D. J. L., Ho, T. H., Bauer, T. M., Lee, C. B., Tchaleu, F. B., Zhu, J. W., Zhang, X., Cha, E., & Sznol, M. (2021) · Current Oncology · doi:10.3390/curroncol28060455 · Cited by 7
Hamza, M., Wang, S., Liu, Y., Li, K., Zhu, M., & Chen, L. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128156 · Cited by 6
Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 9
Mao, Y., Gide, T. N., Maher, N. G., Vignati, D., Boutros, A., Cornejo‐Páramo, P., Potter, A. J., Carlino, M. S., Paver, E. C., Burke, H., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01230-y · Cited by 6
Self-citationYacoub, I., Rayn, K. N., Choi, J. I., Bakst, R. L., Chhabra, A. M., Qian, J. Y., Johnstone, P. A. S., & Simone, C. B. (2024) · Cancers · doi:10.3390/cancers16233920 · Cited by 6
“Nivolumab has also shown improved response rates, PFS, and OS in the Checkmate 037 [87], 066 [88,89], and 067 [90] trials, along with long-term survival in up to 40% of patients, and durable responses that persist even after treatment ends [89].”
Corsini, E. M., Mitchell, K. G., Zhou, N., Bernatchez, C., Forget, M., Haymaker, C., Hofstetter, W. L., Mehran, R. J., Rajaram, R., Rice, D. C., et al. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26548 · Cited by 6
Cardiotoxicity of Systemic Melanoma Treatments
Mukunda, N., Vallabhaneni, S., Lefebvre, B., & Fradley, M. G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00924-2 · Cited by 8
Truong, J., Yeung, S. S. T., Kletas, V., de Lemos, M. L., Schaff, K., & Nakashima, L. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231199048 · Cited by 6
Immunotherapy of Human Melanoma: Past, Present, Future
Mortezaee, K., & Majidpoor, J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673283943240227104122 · Cited by 6
An update on the safety of nivolumab for the treatment of advanced melanoma
Czarnecka, A. M., & Rutkowski, P. L. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1757068 · Cited by 6
“this trial patients with previously untreated BRAF wild-type advanced melanoma were treated with nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxic [48].”
MethodSelf-citationScientifically based combination therapies with immuno‐oncology checkpoint inhibitors
Chew, H. Y., Dolcetti, R., & Simpson, F. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14338 · Cited by 6
“4% and 13% of patients in dacarbazine group showed complete and partial responses respectively [96].”
BackgroundMa, V. T.-L., Daignault‐Newton, S., Waninger, J. J., Journey, S. N., Chopra, Z., Tezel, A., Redman, B. G., Fecher, L. A., Green, M. D., Alva, A. S., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12944 · Cited by 7
“In CheckMate 066, the authors evaluated nivolumab in the first-line setting for metastatic melanoma, but excluded BRAF V600 mutant patients (Ascierto et al., 2019).”
BackgroundMelanoma in Singapore: A 20-year review of disease and treatment outcomes
Yeo, P. M., Lim, Z. V., Tan, W. D. V., Zhao, X., Chia, H. Y., Tan, S. H., Teo, M., & Tan, M. W. P. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2020535 · Cited by 6
Is primary breast melanoma a true pathological entity? The argument against it
Narvaez‐Rojas, A. R., Linhares, S. M., Sedighim, S., Klingbeil, K. D., Milikowski, C., Elgart, G. W., Jaimes, N., Feun, L. G., Lutzky, J., Ku, G. D. L. C., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37224 · Cited by 5
“These drugs have shown to improve PFS and OS [77,78] with tolerable toxicity profiles.”
BackgroundA Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma
Champion, P. J., Bluestein, J. R., Quinn, A. E., Bell, S. D., Kiley, J. H., Wakefield, M. R., & Fang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13061388 · Cited by 6
“A phase III clinical trial (CheckMate 066) demonstrated that drugs such as nivolumab demonstrate a superior increase in five-year overall survival, PFS, and an overall response rate when compared to the standard chemotherapeutic drug dacarbazine [14].”
Wijnen, S. C. M. A., Dimitriadis, P., Wessels, L. F. A., & Blank, C. U. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116711 · Cited by 5
Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?
Namikawa, K., Nakano, E., Ogata, D., & Yamazaki, N. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17147 · Cited by 4
Martínez-Vila, C., González‐Navarro, E. A., Teixidó, C., Martin, R., Aya, F., Juan, M., & Arance, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179506 · Cited by 5
“…based on the results of pivotal trials in which anti-PD-1 monotherapy achieved an objective response rate (ORR) of approximately 35 to 42% and a 7-year OS of 37.8%, demonstrating superiority over chemotherapy (ChT) and anti-CTLA-4 as first-line treatment in patients with advanced melanoma [4,5].”
BackgroundInfluentialSelf-citationPersa, O. D., Schatton, K., Rübben, A., Berking, C., Erdmann, M., Schlaak, M. S., Mauch, C., & Steeb, T. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000375 · Cited by 5
Self-citationEstrada, R. B., Boada, A., Carrera, C., Fernández‐Figueras, M. T., González‐Cao, M., Moreno-Ramírez, D., Nagore, E., Ríos‐Buceta, L., Rodríguez‐Peralto, J. L., Samaniego-González, E., et al. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2020.07.005 · Cited by 5
Martínez-Vila, C., Teixidó, C., Martín, R., Aya, F., Sudhaman, S., Budde, G. L., González‐Navarro, E. A., Alós, L., de Anta, N. C., Ortiz, J. B., et al. (2025) · Cancers · doi:10.3390/cancers17233804 · Cited by 4
“Despite the important advances in treatment strategy in advanced melanoma, 35% of patients experience primary resistance to treatment, 25–45% develop acquired resistance, and all are at risk for treatment-related toxicities [1–6].”
InfluentialSelf-citationImmunotherapy utilization in stage IIIA melanoma: less may be more
Frey, A. E., Kerekes, D. M., Khan, S. A., Tran, T. T. T., Kluger, H. M., Clune, J. E., Ariyan, S., Sznol, M., Ishizuka, J. J., & Olino, K. L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1336441 · Cited by 4
Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
Broderick, J. C., Adams, A. M., Barbera, E. L., Decar, S. G. V., Clifton, G. T., & Peoples, G. E. (2025) · Vaccines · doi:10.3390/vaccines13060656 · Cited by 5
“Despite these gains, up to half of those receiving checkpoint inhibitor therapy (CPI) may not achieve a significant therapeutic response [3,5–7], and they can develop significant toxicity [3,8].”
Lengyel, A., Meznerics, F. A., Galajda, N. Á., Gede, N., Kói, T., Mohammed, A. A., Péter, P. N., Lakatos, A. I. T., Krebs, M., Csupor, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312821 · Cited by 4
Cutaneous Malignancies of the Head and Neck
In, G. K., Thomas, J. S., & Silk, A. W. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.05.008 · Cited by 4
Carlson, K. J., & Volsky, P. G. (2021) · Otology & Neurotology · doi:10.1097/mao.0000000000003293 · Cited by 4
“Phase 3 randomized controlled trials have shown nivolumab offers a survival benefit to patients with advanced cutaneous melanoma (21,22).”
BackgroundWu, M., Wang, Y., Xu, Y., Zhu, J. J., Lv, C., Sun, M., Guo, R., Xia, Y., Zhang, W., & Xue, C. (2019) · Journal of Cancer · doi:10.7150/jca.32638 · Cited by 4
“CHE Gupta 2014 NA NA 32 (84) 19 (50) 28 (74) NA 29 (76) 11 (29) NA NA NA 15 (39) NA 11 (29)”
InfluentialHaferkamp, S., Schilling, B., Berking, C., Drexler, K., Gesierich, A., Tomsitz, D., Erdmann, M., Jakob, L., Geissler, E. K., Zeman, F., et al. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf350 · Cited by 3
Prognosis in stage II melanoma of the head and neck depends on the histological subtype
Jasper, S., Keim, U., Leiter, U., Amaral, T. M. S., Flatz, L., & Forschner, A. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15164 · Cited by 3
Cost-effectiveness of nivolumab in advanced melanoma: a drug review
Specenier, P. M. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1845144 · Cited by 4
Blankenstein, S. A., Bonenkamp, J. J., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers‐Sonderen, M. J., van den Eertwegh, A. J. M., Franken, M. G., de Groot, J. W. B., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12600-2 · Cited by 3
Che, R., Han, D., Wang, F., Liu, H., Fan, M., Yan, H., Xiao, T., Wang, Z., Zhou, X., Wang, X., et al. (2023) · Nano Research · doi:10.1007/s12274-022-5362-7 · Cited by 3
Yokota, K., Takenouchi, T., Fujisawa, Y., Fukushima, S., Uchi, H., Inozume, T., Kiyohara, Y., Uhara, H., Nakagawa, K., Furukawa, H., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17002 · Cited by 3
Are patients in haemodialysis good candidates for immunotherapy treatment?
Fernandez-Diaz, A. B., Tomás, A. J. C., García-Medina, A., Ferrer‐Guillén, B., & Jaime, A. B. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000616 · Cited by 3
Ming, Z., Lim, S. Y., Kefford, R. F., & Rizos, H. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12824 · Cited by 3
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status
van Breeschoten, J., Wouters, M. W. J. M., de Wreede, L. C., Hilarius, D. L., Haanen, J. B. A. G., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. B., Hospers, G. A. P., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000786 · Cited by 3
Clarenne, J., Boulanger, C., Maréchal, A., Visseaux, L., & Slimano, F. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220918019 · Cited by 3
“6% in the nivolumab and dacarbazine groups, respectively.(4) Safety and efficacy of pembrolizumab (Q2W and Q3W) were demonstrated in a large phase III trial (Keynote-006), which randomized patients to pembrolizumab (every two weeks or every three weeks) or ipilimumab, and demonstrated the superiority of the pembrolizu…”
BackgroundPaggio, J. C. D., & Tannock, I. F. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.469 · Cited by 4
Lengyel, A., Kemény, L. V., Meznerics, F. A., Galajda, N. Á., Gede, N., Kói, T., Mohammed, A. A., Péter, P. N., Lakatos, A. I. T., Krebs, M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4765230 · Cited by 3
Ma, Y., Ma, X., Hao, M.-L., Liu, R.-X., Yang, Z., Yang, J., Chen, X., Chen, Y.-N., Zheng, S.-N., Zhang, Y., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01599-3 · Cited by 2
Inhibiting Fatty Acid Oxidation Suppresses Acquired Resistance to Standard Chemotherapy in Melanoma
Choi, W., Ham, W., Park, J., Sim, S. H., Chun, J. W., Kang, M., Kim, C., Hong, W., Koh, E.-B., Kang, J. K., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209873 · Cited by 2
“…of these novel therapeutic strategies, the median overall survival for patients with metastatic melanoma has increased from less than one year during the era of cytotoxic chemotherapy to more than three to five years in the current era of immune checkpoint inhibitors and targeted therapies [4,5].”
Costantini, F., Sano, C. D., Raccosta, S., Manno, M., & Barbieri, G. (2026) · FEBS Journal · doi:10.1111/febs.70414 · Cited by 2
TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression
Zang, N., Gan, J., Chen, Y., Huang, Z., Xie, C., Dang, J., Huang, C., Yang, L., Chen, X., Rong, G., et al. (2026) · 癌症：英文版 · doi:10.34133/cancomm.0021 · Cited by 2
“…protein kinase kinase (MEK) inhibitors [ 6 ], and immune checkpoint blockade (ICB) therapies, including anti-programmed cell death protein 1 (anti-PD-1) [ 7 , 8 ] and anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) antibodies [ 9 , 10 ], long-term outcomes remain suboptimal.”
Ksienski, D., Truong, P. T., Croteau, N. S., Chan, A. M. Y., Sonke, E., Patterson, T., Clarkson, M., & Lesperance, M. (2021) · Cureus · doi:10.7759/cureus.19835 · Cited by 2
Zhang, X., Ding, C., & Zhao, Z. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.09.004 · Cited by 2
Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report
Duarte, R. A., Trigo, F., Luz, I. A., & Santos, P. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000928 · Cited by 2
Mao, Y.-K., Wang, Y., Chen, X., Liu, C., & Bao, Q. (2023) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.16105 · Cited by 2
Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
Ballesteros‐Álvarez, J., & Blázquez‐Medela, A. M. (2024) · DNA · doi:10.3390/dna4040025 · Cited by 2
The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
Mangana, J., Özdemir, B. C., Mihic‐Probst, D., Siano, M., Metaxas, Y., Maul, L. V., Hunger, R. E., Lindenblatt, N., Olariu, R., von Moos, R., et al. (2025) · Swiss Medical Weekly · doi:10.57187/s.4210 · Cited by 2
Yüksel, H. Ç., Acar, C., Şahin, G., Çelebi, G., Tünbekici, S., & Karaca, B. S. (2025) · Medicina · doi:10.3390/medicina61091559 · Cited by 2
“Targeted therapies and newly developed immune checkpoint inhibitors (ICIs) have led to significant improvements in the survival of patients with melanoma [1–3].”
Age‐related next‐generation sequencing mutational analysis in 1196 melanomas
Santamaria‐Barria, J. A., Matsuba, C., Khader, A., Scholar, A. J., Garland‐Kledzik, M., Fischer, T. D., Essner, R., Salomon, M. P., Mammen, J. M. V., & Goldfarb, M. R. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27239 · Cited by 2
Liebers, M. R. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788019958-00345 · Cited by 2
Geometric and Combinatorial Aspects of NonEquilibrium Statistical Mechanics
Polettini, M. (2012) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/4305 · Cited by 2
van Breeschoten, J., van den Eertwegh, A. J. M., de Wreede, L. C., Hilarius, D. L., van Zwet, E. W., Haanen, J. B. A. G., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., et al. (2021) · Cancers · doi:10.3390/cancers13205077 · Cited by 2
“However, compared to randomized clinical trials, 2-year survival probabilities in this cohort study are lower [7,30], possibly due to the inclusion of older patients, more patients with stage IV-M1c disease, and a higher ECOG PS of ≥2 [31].”
BackgroundMelanoma: An immunotherapy journey from bench to bedside
Navani, V., Graves, M. C., Mandaliya, H. A., Hong, M., van der Westhuizen, A., Martin, J. H., & Bowden, N. A. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_2 · Cited by 2
Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease
Fujita, T., Clements, D. M., Premeaux, T. A., & Ndhlovu, L. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_6 · Cited by 2
Targeting Innate Immunity to Treat Cancer
Austin, M., & Kluger, H. M. (2020) · Cancers · doi:10.3390/cancers12102723 · Cited by 2
Tumor Microenvironment: Immune Effector and Suppressor Imbalance
Sheehan, K., & Schalper, K. A. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_1 · Cited by 1
Warshowsky, E. A., McCarthy, M., Wells, K., Arcidiacono, A., Csury, L., & Nitzkorski, J. R. (2024) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2024.109686 · Cited by 1
“There were no deaths due to study drug toxic effects [9].”
Smith-Uffen, M., Park, J., Parsonson, A. O., Kiely, B. E., & Vasista, A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae089 · Cited by 1
Lobo-Martins, S., Martins-Branco, D. A., Semedo, P. M., Alvim, C. M., Monteiro, A. M., Vendrell, I., Gouveia, E. J., Passos, M. J., Costa, L., Mansinho, A., et al. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101043 · Cited by 1
Hasan, M., Samlowski, W. E., & Nakhle, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1827644 · Cited by 1
Chen, Y., Liang, X., Chen, X., & Li, Y. (2026) · Health Science Reports · doi:10.1002/hsr2.72865 · Cited by 1
Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma
Friedlander, P. A., Simpson, W., & Cajulis, C. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-29236-2_6 · Cited by 1
La qualité de vie dans les essais thérapeutiques d’inhibiteurs de checkpoints immunitaires
Coquan, E., & Joly, F. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.05.005 · Cited by 1
Vannas, C., Bjursten, S., Filges, S., Fagman, H., Ståhlberg, A., & Levin, M. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1802064 · Cited by 1
Immunotherapy of Metastatic Melanoma
Jinga, D.-C., & Jinga, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105585 · Cited by 1
Current drug therapy for colorectal cancer
Mohapatra, L., Tripathi, A. S., Alka, Mishra, D. K., Parida, S. K., Yasir, M., Maurya, R. K., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00014-3 · Cited by 1
Pulmonary metastasectomy after immune checkpoint inhibitors in malignant melanoma
Sakanoue, I., Hamaji, M., Ohsumi, A., Nakajima, D., & Date, H. (2024) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/02184923241241583 · Cited by 1
de Anta, N. C., Martin, R., Carrasco, A., Castillo, P., García‐Herrera, A., Albero‐González, R., García, M., Marginet, M., Palau, N., Hernández, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136942 · Cited by 1
“Moreover, wild-type BRAF in AM harbor diverse mutations, of which rates and implications have not been completely elucidated [13,14].”
BackgroundSelf-citationNisar, M. F., Yan, T., Cai, Y., & Wan, C. C. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10468-8 · Cited by 2
Avances presentes y futuros en el tratamiento de melanoma cutáneo
Bravo, M. A., Mantilla, W. A., Ávila, V., Russi, A., & Cervera, S. (2024) · Medicina · doi:10.56050/01205498.2383 · Cited by 1
İmmunoterapi ve Radyoterapi Kombinasyonu
Sarıhan, S. (2020) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.710919 · Cited by 1
Cybulska-Stopa, B., Ziętek, M., Kamińska‐Winciorek, G., Czarnecka, A. M., Piejko, K., Galus, Ł., Ziółkowska, B., Kieszko, S., Kempa-Kamińska, N., Calik, J., et al. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0037 · Cited by 1
Self-citationNivolumab in Melanoma: An Overview of Medical Literature and Future Perspectives
Stucci, L. S., Todisco, A., Mandalà, M., & Tucci, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_11 · Cited by 1
New Therapies in Advanced Cutaneous Malignancies: Conclusions
Rutkowski, P. L., & Mandalà, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_23 · Cited by 1
Self-citationMalignant carcinoma and skin melanoma neoplasms concomitantly in the thyroid
Al‐Harake, A., Dandache, I., Moukadem, H. A., Saliba, M., Chahine, J., Yazbeck, H., Abdel‐Sater, F., Karnib, H. H., & Younes, M. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4790 · Cited by 1
Selective Mitochondrial Respiratory Complex I Subunit Deficiency Causes Tumor ImmunogenicityPreprint
Liang, J., Vitale, T., Zhang, X., Jackson, T. D., Yu, D., Jedrychowski, M. P., Gygi, S. P., Widlund, H. R., Wucherpfennig, K. W., & Puigserver, P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.02.560316 · Cited by 1
Wang, G., Yoon, D., Patel, K., Nandi, A., Azar, T., Kim, J. J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5126088 · Cited by 1
Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_39-1
Metadata
- Authors
- Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L., Arance, A., Svane, I. M., Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J., & Atkinson, V.
- Affiliations
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- The University of Sydney (AU)
- Institut Gustave Roussy (FR)
- Cabrini Hospital (AU)
- Université de Bordeaux (FR)
- UOC Oncological Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
- Inserm (FR)
- Heidelberg University (DE)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Royal Prince Alfred Hospital (AU)
- Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
- BC Cancer Agency (CA)
- Helsinki University Hospital (FI)
- Assistance Publique–Hôpitaux de Paris Dermatology and Centre d’Investigation Clinique, University Paris Diderot INSERM U976, Saint Louis Hospital, Paris, France
- Centre National de la Recherche Scientifique (FR)
- McGill University (CA)
- Melanoma Cancer Unit, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy
- University Hospital Cologne (DE)
- Instituto Nazionale Tumori Regina Elena (IT)
- Sahlgrenska University Hospital (SE)
- Hospital Clínic de Barcelona (ES)
- Herlev Hospital (DK)
- Essen University Hospital (DE)
- National and Kapodistrian University of Athens (GR)
- Bristol-Myers Squibb (United States) (US)
- The University of Queensland (AU)
- Corresponding author
- Ascierto, Paolo A.
- ORCID
- Ascierto, Paolo A.
- Long, Georgina V.
- Robert, Caroline
- Dutriaux, Caroline
- Mortier, Laurent
- Hassel, Jessica C.
- Rutkowski, Piotr
- McNeil, Catriona
- Savage, Kerry J.
- Hernberg, Micaela M.
- Charles, Julie
- Mihalcioiu, Catalin
- Mauch, Cornelia
- Cognetti, Francesco
- Ny, Lars
- Arance, Ana
- Svane, Inge Marie
- Schadendorf, Dirk
- Gogas, Helen
- Saci, Abdel
- Atkinson, Victoria
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-02-01
- Volume
- 5
- Issue
- 2
- Pages
- 187
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6439558
- OpenAlex
- W2898510820
- Cited by
- 352
- References
- 20
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 65 · 2020: 83 · 2019: 33
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- BRAF wild-type melanoma, advanced melanoma, nivolumab, dacarbazine, immune checkpoint inhibitors, PD-1 inhibitors, first-line therapy, overall survival, long-term follow-up, complete response, partial response, treatment-related adverse events, immunotherapy, progression-free survival, treatment discontinuation
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Dacarbazine, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Time Factors, Treatment Outcome, Disease Progression, Antineoplastic Agents, Alkylating, Proto-Oncogene Proteins B-raf, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
